Purpose: To verify tolerance and clinical efficacy of vigabatrin (VGB), a new antiepileptic drug, in an add-on therapy with carbamazepine (CBZ).
Patients And Methods: From september 1993 to december 1996, 35 patients with partial complex seizures (CPC) and CPC plus secondary generalization were treated, with VGB plus CBZ, VGB dose was 1.41 +/- 0.26 (g/die +/- SD) and CBZ 2.28 +/- 0.60 (g/die +/- SD).
Results: Patients were followed-up every 4 months showing an improvement between 61.5% and 68.8% from baseline.
Conclusions: In all patients we observed an improvement during the follow-up period. Side effects were mild and well tolerated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
g/die +/-
8
[efficacy vigabatrin
4
vigabatrin associated
4
associated carbamazepine
4
carbamazepine treatment
4
treatment epilepsy
4
epilepsy follow
4
follow 1993-1996]
4
1993-1996] purpose
4
purpose verify
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!